Skip to main content
Quest Diagnostics

The Diagnosis of Primary Aldosteronism: Testing 2 Screening Approaches in a Large Reference Laboratory Population

ENDO2024

Boston, MA, June 1-4, 2024

Poster presentation: The Diagnosis of Primary Aldosteronism: Testing 2 Screening Approaches in a Large Reference Laboratory Population

Authors: Marcelli M, Bi C, Funder JW, McPhaul MJ

Specialty: Endocrinology, Cardiology, Cardiovascular disease

Related content

Conference Presentation
Positivity Rates of Screening Criteria for Primary Aldosteronism: A Cohort Comparison Study
On-Demand Webinar
How to Close Gaps in Care by Maximizing the Power of Laboratory Stewardship Solutions
On-Demand Webinar
Cardiovascular Clinical Conversations: Inflammatory Markers for Defining Cardiovascular Risk
On-Demand Webinar
Innovative Solutions: LC-MS/MS

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.